Menopause Practice Questions

Q: Which of the following hormonal patterns is characteristic of a postmenopausal woman?

↑LH, ↑ FSH, ↓ estrogen and progesterone. ***↑LH, ↑ FSH, ↓ estrogen and progesterone*** - Menopause occurs due to **ovarian follicular depletion**, leading to a significant decrease in the negative feedback exerted by **estrogen** and **progesterone** on the anterior pituitary and hypothalamus. - This loss of negative feedback causes a dramatic rise in **gonadotropin-releasing hormone (GnRH)**, resulting in characteristically high serum levels of **Follicle-Stimulating Hormone (FSH)** and **Luteinizing Hormone (LH)**. *↓ LH, ↓ FSH, ↑ estrogen and progesterone* - This hormonal profile describes a state of **hypogonadotropic hypogonadism**, often seen in conditions like **Kallmann syndrome** or severe hypothalamic dysfunction. - In postmenopausal women, gonadotropins are elevated, not suppressed, because the **ovarian feedback mechanism** is essentially non-functional. *↑LH, ↓ FSH, ↑ estrogen and progesterone* - This pattern of elevated LH and suppressed FSH is biologically inconsistent with standard **menopausal physiology**. - Elevated **estrogen** levels would typically suppress both gonadotropins via negative feedback, rather than allowing FSH to plummet while LH stays high. *↓ LH, ↑FSH, ↓ estrogen and progesterone* - While this option correctly identifies low **estrogen** levels, it incorrectly suggests that **LH** is decreased. - In menopause, the loss of feedback affects the entire **hypothalamic-pituitary-ovarian axis**, causing profound increases in both **FSH** and **LH**, with FSH usually rising earlier and to higher levels than LH.

Q: Hormone replacement therapy can increase the risk of which of the following conditions?

Breast carcinoma. **Explanation:** The correct answer is **Breast carcinoma**. Hormone Replacement Therapy (HRT), specifically the combined estrogen-progestogen regimen, is associated with an increased risk of breast cancer. This risk is duration-dependent, typically becoming significant after 3–5 years of use. Estrogen promotes the proliferation of mammary epithelial cells, and the addition of progestogen further enhances this mitogenic effect, potentially promoting the growth of pre-existing occult tumors. **Analysis of Incorrect Options:** * **A. Osteoporosis:** HRT is actually **protective** against osteoporosis. Estrogen inhibits osteoclast activity and reduces bone resorption, thereby increasing bone mineral density and reducing the risk of fractures. * **C. Alzheimer’s Disease:** Current evidence suggests HRT does not increase the risk; some studies even suggest a "window of opportunity" where early initiation may be neuroprotective, though it is not indicated for dementia prevention. * **D. Colorectal Cancer:** Combined HRT has been shown to **decrease** the risk of colorectal cancer (by approximately 30% according to the Women's Health Initiative study). **High-Yield Clinical Pearls for NEET-PG:** * **WHI Study Findings:** HRT increases the risk of **Breast Cancer, Stroke, Venous Thromboembolism (VTE), and Coronary Heart Disease (CHD)**. * **Protective Effects:** HRT decreases the risk of **Osteoporotic fractures and Colorectal cancer**. * **Endometrial Cancer:** Unopposed estrogen increases the risk of endometrial cancer; therefore, progestogen must be added in women with an intact uterus. * **Indications:** The primary indication for HRT is the management of moderate-to-severe vasomotor symptoms (hot flashes) and urogenital atrophy.

Q: Estrogen replacement therapy is contraindicated in women with which of the following conditions?

Vasomotor symptoms. **Explanation:** The question asks for the condition where Estrogen Replacement Therapy (ERT) is **not** contraindicated. In medical terminology, if a drug is indicated for a condition, it is not contraindicated. **1. Why "Vasomotor Symptoms" is the correct answer:** Vasomotor symptoms (hot flashes, night sweats) are the **primary clinical indication** for Hormone Replacement Therapy (HRT/ERT). Estrogen effectively stabilizes the thermoregulatory center in the hypothalamus, which becomes dysfunctional due to estrogen deficiency during menopause. Therefore, it is the treatment of choice, not a contraindication. **2. Analysis of Incorrect Options (Absolute Contraindications):** * **Abnormal Genital Bleeding (Option A):** Undiagnosed vaginal bleeding is an absolute contraindication. It must be investigated first to rule out endometrial hyperplasia or malignancy, which estrogen could exacerbate. * **Known Case of Breast Cancer (Option B):** Estrogen is a potent mitogen for breast tissue. It is strictly contraindicated in women with a history of or active estrogen-dependent tumors (Breast or Endometrial cancer). * **Recent Thromboembolism (Option D):** Oral estrogen increases the synthesis of clotting factors in the liver and decreases antithrombin III. This pro-coagulant effect significantly increases the risk of Deep Vein Thrombosis (DVT) and Pulmonary Embolism. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindications for HRT:** Undiagnosed vaginal bleeding, pregnancy, active liver disease, history of VTE/DVT, and estrogen-dependent malignancies. * **Relative Contraindications:** Hypertension, migraine, gallbladder disease, and endometriosis. * **Clinical Tip:** For women with an intact uterus, estrogen must always be combined with **Progesterone** to prevent endometrial hyperplasia/cancer. ERT (estrogen alone) is only for women who have undergone a hysterectomy.

Q: A 47-year-old female presents with menopausal symptoms such as hot flashes and painful intercourse. Which of the following hormones would be expected to be elevated in this patient?

FSH. **Explanation:** The clinical presentation of hot flashes (vasomotor symptoms) and painful intercourse (atrophic vaginitis) in a 47-year-old woman is characteristic of the **perimenopausal transition**. **1. Why FSH is the Correct Answer:** The primary event in menopause is the depletion of the ovarian follicular pool. As the number of follicles decreases, there is a significant decline in the production of **Inhibin B** and **Estradiol**. Under normal physiological conditions, these hormones exert negative feedback on the anterior pituitary. With their decline, this negative feedback is lost, leading to a compensatory and marked **increase in Follicle-Stimulating Hormone (FSH)**. FSH is typically the first hormone to rise and is the most sensitive biochemical marker for ovarian failure. **2. Why the other options are incorrect:** * **Option B (Estrogen):** Estrogen levels (specifically Estradiol) **decrease** during menopause due to follicular exhaustion. Low estrogen is the direct cause of the patient’s symptoms (hot flashes and vaginal atrophy). * **Option C & D:** Since FSH rises and Estrogen falls, these options are physiologically incorrect. **Clinical Pearls for NEET-PG:** * **Diagnostic Threshold:** An FSH level **>40 mIU/mL** is generally considered diagnostic of menopause in the clinical context. * **Earliest Marker:** A rise in FSH is the earliest biochemical change, often occurring while LH levels are still normal. * **LH/FSH Ratio:** In menopause, the LH/FSH ratio reverses (FSH > LH). * **Post-menopausal Estrogen:** The predominant estrogen in post-menopausal women is **Estrone (E1)**, produced by the peripheral conversion of androstenedione in adipose tissue, rather than Estradiol (E2).

Q: What is the diagnostic procedure of choice for postmenopausal bleeding?

Hysteroscopic guided biopsy. **Explanation:** Postmenopausal bleeding (PMB) is a red-flag symptom that must be investigated to rule out endometrial carcinoma. **Why Hysteroscopic Guided Biopsy is the Correct Choice:** While various methods exist to sample the endometrium, **Hysteroscopy with directed biopsy** is now considered the **Gold Standard** and the diagnostic procedure of choice. Its superiority lies in direct visualization of the uterine cavity, allowing the clinician to identify focal lesions (like polyps or localized malignancy) that might be missed by "blind" procedures. It provides the highest sensitivity and specificity for diagnosing endometrial pathology. **Analysis of Other Options:** * **Endometrial Aspiration (e.g., Pipelle):** This is often the **first-line screening investigation** in an OPD setting because it is minimally invasive. However, it is a blind procedure and can miss focal lesions; if results are negative but bleeding persists, further investigation is required. * **Dilatation and Curettage (D&C):** Formerly the gold standard, it is a blind procedure and carries a higher risk of uterine perforation. It has been largely replaced by hysteroscopy because D&C can miss up to 10-25% of endometrial lesions. * **Ultrasound (TVUS):** This is a non-invasive **screening tool**. A Transvaginal Ultrasound (TVUS) measuring an **endometrial thickness (ET) ≤ 4 mm** has a high negative predictive value for malignancy, but it is not a diagnostic procedure as it cannot provide a histological diagnosis. **NEET-PG High-Yield Pearls:** * **Most common cause of PMB:** Senile/Atrophic vaginitis (followed by endometrial atrophy). * **Most serious cause to rule out:** Endometrial Carcinoma (approx. 10% of PMB cases). * **Investigation of choice for focal lesions:** Hysteroscopy. * **Cut-off for ET in PMB:** >4 mm requires mandatory tissue biopsy.

Q: Which of the following investigations is NOT useful for diagnosis in a 55-year-old female presenting with postmenopausal bleeding?

Postcoital test. **Explanation:** The primary objective in evaluating a 55-year-old female with postmenopausal bleeding (PMB) is to rule out **endometrial carcinoma**, which is the most serious cause of this presentation. **Why Postcoital Test is the Correct Answer:** The **Postcoital Test (Huhner test)** is an outdated investigation used in the evaluation of **infertility** to assess the interaction between cervical mucus and sperm. Since a 55-year-old postmenopausal woman is no longer in her reproductive years and the clinical concern is malignancy rather than fertility, this test has no diagnostic value in this scenario. **Analysis of Other Options:** * **Transvaginal USG (TVUSG):** This is the initial screening tool of choice. A high-yield fact for NEET-PG is the **endometrial thickness (ET) cut-off**: an ET of **≤ 4 mm** has a high negative predictive value for endometrial cancer. * **Pap Smear:** While primarily a screening tool for cervical cancer, it is essential in PMB to rule out cervical causes of bleeding. Occasionally, glandular cells from an endometrial primary may also be detected on a Pap smear. * **Endometrial Biopsy:** This is the **gold standard** for definitive diagnosis. It is mandatory if the ET is > 4 mm or if bleeding is persistent/recurrent, regardless of USG findings. **Clinical Pearls for NEET-PG:** * **Most common cause of PMB:** Senile/Atrophic vaginitis or Atrophic endometritis. * **Most concerning cause of PMB:** Endometrial carcinoma (found in ~10% of cases). * **First-line investigation:** Transvaginal USG. * **Gold standard investigation:** Fractional Curettage or Hysteroscopy-guided biopsy.

Q: All except one are true about hormonal changes during menopause?

LH levels fall. In menopause, the primary physiological event is the **depletion of ovarian follicles**. This leads to a significant decrease in the production of Estrogen and Inhibin. ### Why Option B is the Correct Answer (False Statement) In a normal functioning hypothalamic-pituitary-ovarian (HPO) axis, Estrogen and Inhibin provide negative feedback to the pituitary gland. When these levels drop during menopause, the negative feedback is lost. Consequently, the pituitary gland increases the secretion of both **FSH and LH**. Therefore, **LH levels rise**, not fall. ### Explanation of Other Options * **A. FSH levels rise:** This is true. FSH rises more significantly than LH because Inhibin (which specifically suppresses FSH) is no longer produced by the follicles. An FSH level **>40 mIU/mL** is diagnostic of menopause. * **C. GnRH released at maximal frequency:** This is true. Due to the lack of negative feedback from estrogen, the hypothalamus pulses GnRH at its maximum frequency and amplitude to stimulate the pituitary. * **D. AMH levels fall:** This is true. Anti-Müllerian Hormone is produced by granulosa cells of pre-antral and small antral follicles. As the follicular pool depletes, AMH levels drop, often becoming undetectable years before the final menstrual period. ### NEET-PG High-Yield Pearls * **Earliest biochemical marker** of ovarian aging: **Decrease in Inhibin B**, followed by a rise in FSH. * **Most sensitive/reliable marker** for ovarian reserve: **AMH** (Anti-Müllerian Hormone). * **FSH/LH Ratio:** In menopause, FSH increases more than LH, resulting in an **FSH/LH ratio > 1**. * **Estrogen Source:** Post-menopause, the primary circulating estrogen is **Estrone (E1)**, produced by peripheral conversion of androstenedione in adipose tissue (compared to Estradiol/E2 in reproductive years).

Q: Which of the following is a cause of menopause?

Primary ovarian failure. **Explanation:** **1. Why Primary Ovarian Failure is Correct:** Menopause is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is fundamentally a **primary ovarian failure**. As a woman ages, the pool of primordial follicles in the ovary becomes exhausted. These follicles become unresponsive to gonadotropins (FSH and LH). Consequently, estrogen and inhibin levels fall, leading to a loss of negative feedback on the pituitary. This results in the hallmark biochemical finding of menopause: **elevated gonadotropins (Hypergonadotropic Hypogonadism)**, specifically an FSH > 40 IU/L. **2. Why Other Options are Incorrect:** * **Options A & B:** Menopause is not caused by a lack of stimulation from the higher centers. In fact, the hypothalamus and pituitary remain functional and increase their secretions (GnRH and Gonadotropins) in a futile attempt to stimulate the failing ovaries. * **Option C:** While the HPO axis is indeed altered, "deranged functioning" is a vague clinical term. The specific underlying cause is the depletion of the ovarian follicle pool, not a primary defect in the regulatory axis itself. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Biochemical Marker:** A decrease in **Inhibin B** is the earliest sign of a declining ovarian reserve. * **Diagnostic Marker:** **FSH > 40 IU/L** is the gold standard for confirming menopause. * **Estrogen Shift:** Post-menopause, the predominant circulating estrogen changes from **Estradiol (E2)** to **Estrone (E1)**, which is produced by the peripheral conversion of androstenedione in adipose tissue. * **Average Age:** In India, the average age of menopause is approximately **46–48 years** (slightly earlier than the global average of 51).

Q: Which of the following drugs is NOT used for postmenopausal symptoms?

Danazol. **Explanation:** The correct answer is **Danazol**. **1. Why Danazol is the correct answer:** Danazol is a synthetic steroid with strong **androgenic** and anti-estrogenic properties. It suppresses the pituitary-ovarian axis by inhibiting GnRH release. It is primarily used to treat **endometriosis**, fibrocystic breast disease, and hereditary angioedema. Because it induces a hypoestrogenic state, it can actually *cause* or worsen menopausal symptoms (like hot flashes and vaginal dryness) rather than treating them. **2. Why the other options are incorrect:** * **Conjugated Estrogens (Option A):** This is the gold standard for Hormone Replacement Therapy (HRT). It effectively treats vasomotor symptoms (hot flashes) and urogenital atrophy by replacing the declining endogenous estrogen. * **Tibolone (Option B):** A synthetic steroid with estrogenic, progestogenic, and androgenic properties. It is specifically used for postmenopausal symptoms and prevention of osteoporosis, particularly in women who wish to avoid withdrawal bleeding. * **Alendronate (Option C):** A bisphosphonate used to treat **postmenopausal osteoporosis**. While it doesn't treat vasomotor symptoms, it is a standard drug used to manage the long-term skeletal complications of menopause. **3. NEET-PG High-Yield Pearls:** * **First-line for Vasomotor Symptoms:** HRT (Estrogen + Progesterone if the uterus is intact; Estrogen alone if post-hysterectomy). * **Non-Hormonal Treatment:** SSRIs (e.g., Paroxetine), SNRIs (e.g., Venlafaxine), and Gabapentin are used for hot flashes in patients where HRT is contraindicated (e.g., breast cancer). * **Danazol Side Effects:** Hirsutism, acne, weight gain, and deepening of voice (due to androgenic activity).

Question 1

Which of the following hormonal patterns is characteristic of a postmenopausal woman?

Accepted Answer

↑LH, ↑ FSH, ↓ estrogen and progesterone

Answer

↓ LH, ↓ FSH, ↑ estrogen and progesterone

Answer

↑LH, ↓ FSH, ↑ estrogen and progesterone

Answer

↓ LH, ↑FSH, ↓ estrogen and progesterone

Question 2

Hormone replacement therapy can increase the risk of which of the following conditions?

Accepted Answer

Breast carcinoma

Answer

Osteoporosis

Answer

Alzheimer's disease

Answer

Colorectal cancer

Question 3

You see four postmenopausal patients in the clinic. Each patient has one of the conditions listed, and each patient wishes to begin hormone replacement therapy today. Which patient would you start on therapy at the time of this visit?

Accepted Answer

Mild essential hypertension with tension headache

Answer

Liver disease with abnormal liver function tests

Answer

Treated stage III endometrial cancer

Answer

Undiagnosed genital tract bleeding

Question 4

Estrogen replacement therapy is contraindicated in women with which of the following conditions?

Accepted Answer

Vasomotor symptoms

Answer

Abnormal genital bleeding

Answer

Known case of breast cancer

Answer

Recent thromboembolism

Question 5

A 47-year-old female presents with menopausal symptoms such as hot flashes and painful intercourse. Which of the following hormones would be expected to be elevated in this patient?

Accepted Answer

FSH

Answer

Estrogen

Answer

Both FSH and Estrogen

Answer

Neither FSH nor Estrogen

Question 6

What is the diagnostic procedure of choice for postmenopausal bleeding?

Accepted Answer

Hysteroscopic guided biopsy

Answer

Endometrial aspiration

Answer

Dilatation and curettage

Answer

Ultrasound

Question 7

Which of the following investigations is NOT useful for diagnosis in a 55-year-old female presenting with postmenopausal bleeding?

Accepted Answer

Postcoital test

Answer

Transvaginal USG

Answer

Pap smear

Answer

Endometrial biopsy

Question 8

All except one are true about hormonal changes during menopause?

Accepted Answer

LH levels fall

Answer

FSH levels rise

Answer

GnRH released at maximal frequency

Answer

AMH levels fall

Question 9

Which of the following is a cause of menopause?

Accepted Answer

Primary ovarian failure

Answer

Ovarian failure secondary to cessation of pituitary secretion of gonadotropins

Answer

Ovarian failure secondary to cessation of hypothalamic secretion of GnRH

Answer

Deranged hypothalamic-pituitary-ovarian axis functioning

Question 10

Which of the following drugs is NOT used for postmenopausal symptoms?

Accepted Answer

Danazol

Answer

Conjugated estrogens

Answer

Tibolone

Answer

Alendronate

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?